Ro vs Enhance MD
Two GLP-1 desks, one scoreboard. We put Ro and Enhance MD head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 85 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Enhance MD a bad call — it's best for readers who want to see the whole price ladder before they commit and value dose-flat billing plus routine lab work — and who don't need brand-name or oral options. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Enhance MD | |
|---|---|---|
| Brief Score | 87/100 (B+) | 85/100 (B) |
| Semaglutide | Not disclosed | $212/mo |
| Tirzepatide | Not disclosed | $280/mo |
| Coverage | Multi-state | Not publicly listed |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Enhance MD: Tiered rates held flat; the $112 first-month teaser resets to $212, and the desk still publishes every step on the ladder.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.